Understanding culprits behind fibroid tumors

October 14, 2013

(Medical Xpress)—Tremendous progress has been made in understanding how uterine fibroid tumors—the most common tumor in women – start and grow. A new paper in the New England Journal of Medicine synthesizes the latest research on the role of the hormone progesterone, stem cells and tumor mutations that together offer a new direction for research and drug development.

"These findings represent a paradigm shift in how we will approach new treatments," said article author Serdar Bulun, M.D., the chair of obstetrics and gynecology at Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital.

Bulun's research about how and the tumor's engineer its uncontrolled growth largely shapes the new thinking about these tumors.

"This will shift the way people think about fibroids in research and drug development," Bulun said. "They will now target this crosstalk between stem cells, growth factors and progesterone and specifically target only 1 to 5 percent of all cells in a fibroid. In the past, it was a shotgun approach when we were trying to shrink these tumors by attempting to affect 100 percent of the cells indiscriminately; then the treatment strategy gets diluted and causes severe side effects such as hot flashes and bone loss. If you target the tumor stem cell population in a laser sharp manner, then it is much more likely to be successful with minimal side effects."

By the time women reach 50 years of age, nearly 70 percent of white women and more than 80 percent of black women will have had at least one fibroid; severe symptoms develop in 15 to 30 percent of these women. Uterine fibroids in black women are significantly larger at diagnosis than those in white , are diagnosed at an earlier age, and are characterized by more severe symptoms and a longer period of sustained growth.

Approximately 200,000 hysterectomies, 30,000 myomectomies, and thousands of selective uterineartery embolizations and high-intensity focused ultrasound procedures are performed annually in the United States to remove or destroy uterine fibroids. The annual economic burden of these tumors is estimated to be between $5.9 billion and $34.4 billion.

In 2009, Bulun and colleagues, Julie Kim, Debabrata Chakravarti, Erica Marsh, Takeshi Kurita, and JianJun Wei from Northwestern, and Romana Nowak from University of Illinois at Urbana-Champaign received a P01 grant to sustain the only National Institutes of Health supported comprehensive uterine fibroid research center in the country. In June 2010, scientists at Feinberg, led by Kurita, redefined the roles that estrogen and progesterone play in a discovery that set the stage for major findings to come. That paper, published in Endocrinology, provided proof that estrogen acts in a permissive rather than causative role in uterine fibroid formation. The sex steroid works to prepare uterine tissue to respond to progesterone and progesterone receptor, and it is these hormones that promote tumor growth.

"By identifying a plausible mechanism of tumor growth, our work triggered the field to develop a drug that has already been approved in the European Union and Canada," Bulun said. "Two papers published in 2012 in the New England Journal verified the role of progesterone and demonstrated the efficacy of an anti-progesterone drug to treat fibroids."

If the drug is introduced in the U.S. in the near future, as Bulun suspects, it will mark the first time since the early '90s that a new will be offered to fight uterine fibroids.

Although the cellular origin of uterine fibroids remains unknown, several observations support the notion that each fibroid originates from the transformation of a single somatic, or adult, stem cell.

In a 2011 paper published in Science, a somatic single-gene defect was found in a majority of uterine fibroid tumors. The group of mutations affects the gene encoding MED12, and though not well understood, the gene is mutated in 80 percent of all fibroids.

The following year, Bulun's lab revealed in a PLOS ONE publication that the growth of human fibroid tumors, dependent on estrogen and progesterone, also require the presence of these stem cells, which make up just one percent of the . Most importantly, Bulun's group reported that fibroid stem cells, but not the stem cells from the surrounding uterine tissue, carried MED12 mutations.

Bulun thinks scientists will now seek to develop treatment strategies that target the small stem cell population present in in an effort to develop new treatment options.

Explore further: A single stem cell mutation triggers fibroid tumors

Related Stories

A single stem cell mutation triggers fibroid tumors

May 4, 2012
Fibroid uterine tumors affect an estimated 15 million women in the United States, causing irregular bleeding, anemia, pain and infertility. Despite the high prevalence of the tumors, which occur in 60 percent of women by ...

New study shows uterine fibroids have greater impact in African-American women

October 9, 2013
A national survey has found that uterine fibroids have a disproportionate impact on African American women, causing more severe symptoms, interfering with their daily life, and causing them to miss work. These new findings ...

Genetic risk for uterine fibroids discovered

October 4, 2012
Uterine fibroids are the most common type of pelvic tumors in women and are the leading cause of hysterectomy in the United States. Researchers from Brigham and Women's Hospital (BWH) are the first to discover a genetic risk ...

Abuse during childhood linked to uterine fibroids in African-American women

January 24, 2013
According to a new study from the Slone Epidemiology Center (SEC) at Boston University, African-American women who reported sexual or physical abuse before age 11 had a greater risk of uterine fibroids in adulthood compared ...

Fibroid tumors not risk factor in twin pregnancies

January 30, 2013
(HealthDay)—There does not appear to be an increased risk for complications in twin pregnancies with fibroid tumors compared with those without fibroid tumors, according to research published in the January issue of the ...

Recommended for you

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.